Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.
- CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.
- Successful completion of mass dose escalation study establishes a baseline dosing schedule for future studies of TLX592 using actinium-225.
- MELBOURNE, Australia, May 21, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.
- TLX592 (225Ac-PSMA-RADmAb®) is Telix’s investigational “next generation” targeted alpha therapy (TAT) for the treatment of prostate cancer and is the first clinical program to utilise Telix’s proprietary RADmAb® engineered antibody technology.